Product information - Europe

By accessing this part of the Teoxane.com site (hereinafter referred to as the "Site"), operated and owned by Teoxane SA, you accept the terms of use of the Site (hereinafter referred to as the "Terms of Use") to use the Site. You will access part of the Site which provides access to patient information regarding Teoxane products (Class III Medical Devices) intended for the general public based in Europe. By accessing or using this part of the Site, you acknowledge that you have read, understood and accepted the Terms of Use. If you disagree with any part of these Terms of Use or the Site, you may not access the Site or this page. TEOXANE reserves the right to modify the information contained on the Site or this page at any time; we therefore recommend that users refer to it regularly. The information provided on this Site is presented for informational and educational purposes, and is intended for general public based in Europe. The information made available aims to strengthen, and not to replace, the relationship established between the patient and the healthcare professional.
1. What TEOSYAL® products are and what they are used for
1.1 Description of TEOSYAL® products
TEOSYAL® products are dermal fillers which are sterile injectable viscoelastic hyaluronic acid gels (of non-animal origin) and containing lidocaine (0.3%) to help reduce discomfort during injection. TEOSYAL® products contain residual traces (< 1 ppm) of BDDE (1,4-Butanediol diglycidyl ether) which is used as crosslinking agent.
The composition of the TEOSYAL® PureSense products is presented in the below
- TEOSYAL® PureSense Redensity 1:
- Hyaluronic acid: 15 mg/ml
- Phosphate buffer: N/A
- Supplemented Phosphate Buffer: q.s. ad 1 ml or 3 ml
- Lidocaine: 0.3% by mass
- TEOSYAL® PureSense Redensity 2:
- Hyaluronic acid: 15 mg/ml
- Phosphate buffer: N/A
- Supplemented Phosphate Buffer: q.s. ad 1 ml
- Lidocaine: 0.3% by mass
- TEOSYAL® PureSense Global Action:
- Hyaluronic acid: 25 mg/ml
- Phosphate buffer: q.s. ad 1 ml
- Supplemented Phosphate Buffer: N/A
- Lidocaine: 0.3% by mass
- TEOSYAL® PureSense Deep Lines:
- Hyaluronic acid: 25 mg/ml
- Phosphate buffer: q.s. ad 1 ml
- Supplemented Phosphate Buffer: N/A
- Lidocaine: 0.3% by mass
- TEOSYAL PureSense Kiss®:
- Hyaluronic acid: 25 mg/ml
- Phosphate buffer: q.s. ad 1 ml
- Supplemented Phosphate Buffer: N/A
- Lidocaine: 0.3% by mass
- TEOSYAL® PureSense Ultra Deep:
- Hyaluronic acid: 25 mg/ml
- Phosphate buffer: q.s. ad 1.2 ml
- Supplemented Phosphate Buffer: N/A
- Lidocaine: 0.3% by mass
- TEOSYAL® PureSense Ultimate:
- Hyaluronic acid: 22 mg/ml
- Phosphate buffer: q.s. ad 1 ml or 3ml
- Supplemented Phosphate Buffer: N/A
- Lidocaine: 0.3% by mass
- TEOSYAL® RHA 1:
- Hyaluronic acid: 15 mg/ml
- Phosphate buffer: q.s. ad 1 ml
- Supplemented Phosphate Buffer: N/A
- Lidocaine: 0.3% by mass
- TEOSYAL® RHA 2:
- Hyaluronic acid: 23 mg/ml
- Phosphate buffer: q.s. ad 1 ml
- Supplemented Phosphate Buffer: N/A
- Lidocaine: 0.3% by mass
- TEOSYAL® RHA 3:
- Hyaluronic acid: 23 mg/ml
- Phosphate buffer: q.s. ad 1 ml
- Supplemented Phosphate Buffer: N/A
- Lidocaine: 0.3% by mass
- TEOSYAL® RHA 4 :
- Hyaluronic acid: 23 mg/ml
- Phosphate buffer: q.s. ad 1.2 ml
- Supplemented Phosphate Buffer: N/A
- Lidocaine: 0.3% by mass
- TEOSYAL RHA KISS®:
- Hyaluronic acid: 23 mg/ml
- Phosphate buffer: q.s. ad 0.7 ml
- Supplemented Phosphate Buffer: N/A
- Lidocaine: 0.3% by mass
1.2 Categories of users and consumers
To minimize the risk of potential complications, the TEOSYAL® products should be administered only by healthcare professionals who received appropriate training on the conditions to safely use the device. The product should not be injected in patients who are less than 18 years old and having any of the contra-indications referenced in the instruction for use of the products.
1.3 Expected performance of the products
The following aesthetic results are expected when you receive an injection of TEOSYAL® products:
- TEOSYAL® PureSense Global Action: Creates a volume that corrects wrinkles, cutaneous depressions and restores skin hydration. It may also add volume to the lips and/or enhance their contour.
- TEOSYAL® PureSense Deep Lines: Creates a volume that correct wrinkles, cutaneous depressions, and restores skin hydration.
- TEOSYAL PureSense Kiss®: Creates a volume that corrects cutaneous depressions and restores skin hydration. It may also add volume to the lips and/or enhance their contour
- TEOSYAL® PureSense Ultra Deep: Creates a volume that corrects wrinkles or facial contours and restores skin hydration.
- TEOSYAL® PureSense Ultimate: Creates a volume that corrects facial contours and restores skin hydration.
- TEOSYAL® PureSense Redensity 1: Thanks to its marked fluidity and its viscoelastic properties, it is evenly distributed, ensuring an optimal level of hydration and leading to a lasting improvement in the skin’s texture and elasticity.
- TEOSYAL® PureSense Redensity 2: Creates a volume that corrects fine lines/wrinkles and restores skin hydration.
- TEOSYAL® RHA 1: Thanks to its malleability and its specific viscoelastic properties, it is evenly distributed into the tissue injected, ensuring an optimal level of dermal hydration and leading to a lasting improvement in skin elasticity.
- TEOSYAL® RHA 2: Creates a volume that correct wrinkles, cutaneous depressions and restores skin hydration. It may also add volume to the lips and/or enhance their contour.
- TEOSYAL® RHA 3: Creates a volume that correct wrinkles, cutaneous depressions and restores skin hydration. It may also add volume to the lips and/or enhance their contour.
- TEOSYAL® RHA 4 : Creates a volume that corrects wrinkles, cutaneous depressions and restores skin hydration.
- TEOSYAL RHA KISS®: Creates a volume that corrects wrinkles, cutaneous depressions and restores skin hydration. It may also add volume to the lips and/or enhance their contour.
2. What you need to know before you are given TEOSYAL® products
2.1 Contra-indications
Are there any reasons why you should not receive TEOSYAL® products?
Prior to any injection of TEOSYAL® products, your injector must ask you about your past medical history and your current condition or medication that could affect the procedure. So, you should inform the injector about recent or current pathologies, as well as chronic illnesses, chronic or current allergies, and chronic or ongoing treatments.
You must report to your injector, aesthetic treatments performed previously. Due to the absence of data concerning the possible interactions with other filling implants (HA filling implants or other, possibly permanent), your injector will assess and decide on further injections with other filling implants, depending on the nature and the time of the previous injection.
Especially, you should not use TEOSYAL® products if:
- You have any cutaneous disorders, inflammation, or infection at or near the treatment site. Injection procedures can lead to reactivation of latent or subclinical herpes viral infections.
- You are allergic to hyaluronic acid, with a history of severe allergy or anaphylactic shock.
- You are allergic to lidocaine and/or amide local anesthetic agents.
- you recently had a peeling, laser or ultrasound-based treatment.
- you have any autoimmune diseases.
- you have any cardiac diseases and/or undergoing treatment for heart disease (beta blockers).
- you have any hepatocellular insufficiency and/or undergoing treatment for a liver disease.
- you are suffering from epilepsy or porphyria.
- you are pregnant, or a breast-feeding mother, or a patient less than 18 years old.
2.2 Precautions
Are there precautions that you should discuss with your injector?
Your injector should inform you about the indications, expected outcomes, contraindications, precautions, and potential side effects.
Before the injection, the following precautions should be considered:
- Avoid getting an injection if you have had a dental procedure within the previous 15 days.
- Avoid taking aspirin, anti-inflammatory drugs, anticoagulants, and vitamin E during the week prior to the injection. Ask your doctor for advice prior to stopping any treatment.
- Avoid drinking alcohol or exposing yourself to strong sunlight the day before and the day of the injection.
- Remove your make-up thoroughly prior to the injection.
After the injection, the following recommendations must be considered:
- Within 12 hours following the injection: do not apply make-up, avoid any violent effort.
- During the week following the treatment: avoid drinking alcohol, prolonged exposure to the sun or UV rays, temperatures below 0°C, as well as the practice of sauna or hammam.
- Within 15 days following the treatment: do not perform dental or other aesthetic procedures
2.3 Possible side effects (risks linked to the use of TEOSYAL® products)
What possible reactions could occur following the injection?
As with all hyaluronic acid-based products, the following side effects can be seen after the injection of TEOSYAL® PureSense products:
Common treatment reactions (≥1/100) at the injection site, usually mild and self-resolving: pain at the point of injection, tenderness, redness/erythema, bruising/haematomas with potential bleeding and/or blister formation, swelling/oedema, firmness/induration, lumps/bumps (including papules), itching.
Probable but less common complications (≥1/1,000 and ≤1/100): dyschromia/discoloration, inflammatory reactions (with potential hyperthermia), infection (including localized or generalized infection, abscesses), loss of sensitivity around the injected area or temporary paresthesia (with potential associated transient movement impairment), risk of allergy (including hypersensitivity, dermatitis allergy, urticaria), nodules (possibly granuloma), implant migration.
Rare but serious adverse events may occur (≤1/1,000): immediate hypersensitivity which may even lead to anaphylactic shock, vascular complications which may extend to necrosis of the injected area. Although extremely rare (about 1/1,000,000), most serious cases of vascular occlusion may lead to visual disturbances or even blindness, cerebral ischemia/ hemorrhage leading to stroke which can cause death.
A post-administration monitoring of 30 minutes is strongly recommended to allow the injector to detect any serious immediate incidents.
Reporting of side effects:
In case of dissatisfaction with the expected aesthetic result or if any side effects occurred following treatment with a TEOSYAL® product, you should immediately contact your injector and/or TEOXANE Laboratories:
00 41 (0) 22 344 96 36 - medical@teoxane.com
Most of the reactions described above are gone within one week after the injection, however, you must see a doctor if your symptoms persist.
3. Expected lifetime of the products and any necessary follow-up
The lifetime of the product is understood as the duration of the aesthetic effect. It depends on several factors including skin type, the severity of the wrinkle to be treated, the injected area, the injected volume, the patient’s physiology, and lifestyle.
Your injector will choose the product suitable for injection according to your needs and taking into account your request and will tell you if a touch up session may be required for optimal results.
The estimated lifetime of TEOSYAL® PureSense products are provided in the below
Estimated in vivo lifetime of at least 3 months:
- TEOSYAL® PureSense Redensity 1
Estimated in vivo lifetime of at least 12 months:
- TEOSYAL® PureSense Redensity 2
- TEOSYAL® RHA 1
Estimated in vivo lifetime between 12 to 18 months:
- TEOSYAL® PureSense Global Action
- TEOSYAL® PureSense Deep Lines
- TEOSYAL PureSense Kiss®
- TEOSYAL® RHA 2
- TEOSYAL® RHA 3
- TEOSYAL RHA KISS®
Estimated in vivo lifetime between15 to 18 months:
- TEOSYAL® PureSense Ultra Deep
- TEOSYAL® RHA 4
4. Reference to any harmonized standard and common specifications
Some harmonized standards and Common specifications apply to the TEOSYAL® PureSense products. The complete list is available in the Summary of Safety and Clinical Performance (SSCP) which is available on Eudamed at the following website: ec.europa.eu/tools/eudamed/#/screen/home.
History of the document:
Teoxane Dermal Fillers Instruction for patients_EN_Rev00 : Revision date : 13.06.2023